Recent Updates
Recently added Catalysts

Influenza Vaccine, Inactivated

Phase 3

Seasonal Influenza | Monoclonal antibody | Infectious Disease |Sinovac Biotech, Ltd|Last Updated: Jul 30, 2026

Target and mechanism

ModalityMonoclonal antibody

Also known as Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Influenza Vaccine, Inactivated, Quadrivalent

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment2,202

FDA Designations

No designations recorded

Clinical trial landscape

Influenza Vaccine, Inactivated · 2 trials · 2 indications

Phase 3 1Phase 1 1
NCT05431725Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, QuadrivalentSeasonal Influenza
COMPLETED2,202 Analytics
PHASE3COMPLETED
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Seasonal InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

Seroconversion rates of HI antibody
At day 28 after the last dose

Seroconversion rates of HI antibody at day 28 after the last dose for each of the four antigens.

GMTs of HI antibody
At day 28 after the last dose

GMTs of HI antibody at day 28 after the last dose for each of the four antigens.

Incidence of Adverse Reactions
Day 0 to Day 28 after vaccination

Secondary Endpoints

Seroprotection rates(SCRs) of HI antibody
At day 28 after the last dose
Seroconversion rates (SCRs) of HI antibody
At day 28 after the last dose
Solicited local and systemic Adverse Events (AEs)
Within 7 days after each dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Sinovac-QIV groupEXPERIMENTAL800 subjects aged 3 years and older will receive one dose of Sinovac-QIV for vaccine-primed subjects or two doses of Sinovac-QIV for vaccine-unprimed subjects.
Vaxigrip Tetra-QIV groupACTIVE_COMPARATOR800 subjects aged 3 years and older will receive one dose of Vaxigrip Tetra-QIV for vaccine-primed subjects or two doses of Vaxigrip Tetra-QIV for vaccine-unprimed subjects.
Influenza Vaccine (Split Virion), Inactivated (High Dose)EXPERIMENTALParticipants will receive one dose of Influenza Vaccine (Split Virion), Inactivated (High Dose).
Influenza Vaccine (Split Virion), InactivatedACTIVE_COMPARATORParticipants will receive one dose of the active control influenza vaccine.

Interventions

NameTypeDescription
Influenza Vaccine (Split Virion), Inactivated, QuadrivalentBIOLOGICALThe influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
Control Quadrivalent influenza virus vaccineBIOLOGICALThe Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
Influenza Vaccine (Split Virion), Inactivated (High Dose)BIOLOGICALA single 0.5 mL dose of the investigational high-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 60 μg of hemagglutinin from each influenza virus strain used for the current influenza season.
Influenza Vaccine (Split Virion), InactivatedBIOLOGICALA single 0.5 mL dose of the active control standard-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 15 μg of hemagglutinin from each influenza virus strain used for the current influenza season.
Unlock Study Design Details

Eligibility Criteria

Age Range3 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites11

Inclusion Criteria: * Volunteers age 3 years and older, in good health or medically stable; * Written informed consent obtained from subjects or/and legal guardian; * No receipt of influenza vaccines within 6 months or plans to receive any influenza vaccines during the study; * Female subjects of n...

Countries:ChilePhilippinesChina
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 30, 2026NCT07737106TRIAL_REMOVED: changed
MEDIUMAug 30, 2026NCT07737106TRIAL_REMOVED: changed
MEDIUMAug 30, 2026NCT07737106TRIAL_REMOVED: changed
LOWJul 30, 2026NCT07737106NEW_TRIAL: changed
LOWJul 30, 2026NCT07737106NEW_TRIAL: changed